tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BTAI Stock Latest News

BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results
RatingsBioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results
22h ago
BTAI
BioXcel Submits IGALMI® Application for FDA Review
PremiumCompany Announcements
BioXcel Submits IGALMI® Application for FDA Review
2d ago
8K
BTAI
BioXcel Therapeutics submits pre-supplemental NDA meeting package for IGALMI
PremiumThe Fly
BioXcel Therapeutics submits pre-supplemental NDA meeting package for IGALMI
2d ago
BTAI
Lucid reiterates Buy on BioXcel after patent application approval
PremiumThe Fly
Lucid reiterates Buy on BioXcel after patent application approval
8d ago
BTAI
BioXcel Therapeutics announces patent allowance for dexmedetomidine
PremiumThe Fly
BioXcel Therapeutics announces patent allowance for dexmedetomidine
8d ago
BTAI
BioXcel Granted Patent for Dexmedetomidine Use
PremiumCompany AnnouncementsBioXcel Granted Patent for Dexmedetomidine Use
8d ago
8K
BTAI
Positive Buy Rating for Bioxcel Therapeutics Driven by Promising Phase 3 Trial Developments and Valuation Alignment
Premium
Ratings
Positive Buy Rating for Bioxcel Therapeutics Driven by Promising Phase 3 Trial Developments and Valuation Alignment
20d ago
BTAI
BioXcel Therapeutics reports DSMB recommends continuation of SERENITY trial
Premium
The Fly
BioXcel Therapeutics reports DSMB recommends continuation of SERENITY trial
22d ago
BTAI
BioXcel Therapeutics initiated with a Buy at Lucid Capital
PremiumThe Fly
BioXcel Therapeutics initiated with a Buy at Lucid Capital
28d ago
BTAI
BioXcel Therapeutics target adjusted to $8 from $3 at H.C. Wainwright
PremiumThe Fly
BioXcel Therapeutics target adjusted to $8 from $3 at H.C. Wainwright
30d ago
BTAI
BioXcel receives positive recommendation from DSMB for SERENITY Phase 3 trial
PremiumThe Fly
BioXcel receives positive recommendation from DSMB for SERENITY Phase 3 trial
2M ago
BTAI
BioXcel Granted Nasdaq Compliance Extension Until September
PremiumCompany Announcements
BioXcel Granted Nasdaq Compliance Extension Until September
2M ago
8K
BTAI
BioXcel granted extension to regain compliance with Nasdaq listing requirement
PremiumThe FlyBioXcel granted extension to regain compliance with Nasdaq listing requirement
2M ago
BTAI
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments
Premium
Company Announcements
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments
2M ago
BTAI
BioXcel Therapeutics reports Q1 EPS ($1.50) vs. ($13.89) last year
Premium
The Fly
BioXcel Therapeutics reports Q1 EPS ($1.50) vs. ($13.89) last year
2M ago
BTAI
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses
PremiumCompany Announcements
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses
4M ago
BTAI
BioXcel Therapeutics price target lowered to $1 from $4 at BofA
PremiumThe Fly
BioXcel Therapeutics price target lowered to $1 from $4 at BofA
4M ago
BTAI
BioXcel Therapeutics reports Q4 EPS ($3.57), consensus ($5.14)
PremiumThe Fly
BioXcel Therapeutics reports Q4 EPS ($3.57), consensus ($5.14)
4M ago
BTAI
BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
4M ago
BTAI
Mind Medicine appoints Matt Wiley as CCO
PremiumThe FlyMind Medicine appoints Matt Wiley as CCO
4M ago
BTAI
MNMD
BioXcel Therapeutics strengthens cash position to advance SERENITY trial
Premium
The Fly
BioXcel Therapeutics strengthens cash position to advance SERENITY trial
4M ago
BTAI
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial
Premium
The Fly
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial
5M ago
BTAI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >